Hepatitis A vaccine: Is it being used to best advantage?

Scheifele, David W.; Ochnio, Jan
July 2002
CMAJ: Canadian Medical Association Journal;7/9/2002, Vol. 167 Issue 1, p44
Academic Journal
Questions whether the Hepatitis A vaccine is being used to the best advantage. How the infection has caused substantial morbidity in children of school age and adults; Symptoms, which include prolonged nausea, anorexia and weakness; How Hepatitis A virus vaccines are remarkably immunogenic, requiring only a single dose to induce protection and one later dose to sustain for many years.


Related Articles

  • The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta-analysis. Fisman, David N.; Agrawal, Deepak; Leder, Karin // Clinical Infectious Diseases;12/1/2002, Vol. 35 Issue 11, p1368 

    Hepatitis B vaccine is a key tool for the prevention of hepatitis B infection. Age-associated changes in immune function may contribute to decreased vaccine efficacy in older individuals, although research related to this topic has yielded contradictory findings. We performed a meta-analysis of...

  • A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kong, N. C. T.; Beran, J.; Kee, S. A.; Miguel, J. L.; Sánchez, C.; Bayas, J.-M.; Vilella, A.; Calbo-Torrecillas, F.; López de Novales, E.; Srinivasa, K.; Stoffel, M.; Hoet, B. // Kidney International;Apr2008, Vol. 73 Issue 7, p856 

    Prehemodialysis and hemodialysis patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this population. We measured antibody...

  • CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection. Angel, Jonathan B.; Cooper, Curtis L.; Clinch, Jennifer; Young, Charlene D.; Chenier, Andreane; Parato, Karl G.; Lautru, Michael; Davis, Heather; Cameron, Donald W. // Journal of Immune Based Therapies & Vaccines;2008, Vol. 6, Special section p1 

    Background: Lack of adequate adjuvancy is a possible explanation for lack of vaccine immunogenecity. Immunostimulatory CpGs are potent vaccine adjuvants and may be an important component of the development vaccines, particularly those for which a cellular immune response is required for...

  • Failure of Hepatitis B Immunization in Liver Transplant Recipients: Results of a Prospective Trial. Carey, William; Pimentel, Ronnie; Westveer, Mary Kay; Vogt, David; Broughan, Thomas // American Journal of Gastroenterology;Dec1990, Vol. 85 Issue 12, p1590 

    Twenty patients with advanced liver disease, in need of transplantation, were given three injections of 20 µg and three injections of 40 µg hepatitis B vaccine to see if an antibody response could be obtained. Only 20% of patients developed measurable anti-HBs. One who failed to develop...

  • Investigation (In Vivo and In Vitro) of Booster Dose Vaccine Requirement for Long-Term Protection against Hepatitis B Virus Infection. Saygun, Onur; Eyigün, Can Polat; Avci, Ismail Yaşar; Kisa, Üçler; Pahsa, Alaaddin // Turkish Journal of Medical Sciences;2009, Vol. 39 Issue 2, p173 

    Aim: Studies have shown that no booster dose was required at least 10 to 15 years after a primary vaccination for individuals who developed protective anti-hepatitis B surface (anti-HBs) antibodies. In this study, booster dose requirement for HBV after primary immunization was investigated....

  • A study of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Bogdanos, Dimitrios-Petrou; Smith, Heather; Yun Ma; Baum, Harold; Mieli-Vergani, Giorgina; Vergani, Diego // Clinical & Developmental Immunology;Sep2005, Vol. 12 Issue 3, p217 

    On the basis of the reported association between hepatitis B vaccination (HBvacc) and autoimmune demyelinating complications such as multiple sclerosis (MS), we have looked for aminoacid similarities between the small hepatitis B virus surface antigen (SHBsAg), and the MS-autoantigens myelin...

  • No scientific justification to suspend hepatitis B immunization.  // Public Health Reports;Nov/Dec98, Vol. 113 Issue 6, p487 

    Discusses the issue that hepatitis B immunization might be linked to the development of demyelinating disease. Scientific evidence on whether HB vaccine can cause multiple sclerosis (MS) according to the World Health Organization (WHO); Concern of WHO over France's decision to suspend routine...

  • Breakthrough Hepatitis B Virus (HBV) Infection From Mother-to-Infant Transmission Is the Key Problem Hindering HBV Eradication. Su, Wei-Ju; Chen, Huey-Ling; Chang, Mei-Hwei // Journal of Infectious Diseases;Sep2013, Vol. 208 Issue 6, p1036 

    A letter to the editor is presented related to a study, which illustrates that infants, who were born to mothers with positive and negative hepatitis B virus (HBV) e-antigen (HBeAg), developed acute hepatitis in Taiwan and suggests decline in HBV immunoglobulin vaccine potential.

  • Hepatitis B vaccine efficacy in HCV vertical infected infants. Aniszewska, Malgorzata; Kowalik-Mikolajewska, Barbara; Pokorska-Lis, Maria // Retrovirology;2008 Supplement 1, Vol. 5, Special section p1 

    Aim The aim of the study was to evaluate the immunogenicity of hepatitis B vaccine after primary immunization in children vertically infected with HCV. Patients and methods 105 infants born to HCV infected mothers were vaccinated against hepatitis B virus (recombinant vaccine, 10 µg, 0-1-6...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics